Sign in

NNNN on Nasdaq

Anbio Biotechnology

Anbio Biotechnology is an in vitro and in vivo diagnostic substances company, active since 2021.2 It is headquartered in Grand Cayman, Cayman Islands.2 Its shares trade on Nasdaq under the symbol NNNN.2

Price unavailable

Last updated Oct 21, 2026.

Overview

$8.6MRevenue, fiscal 20253
$6.4MNet income, fiscal 20253

Compare with Aspira Women's Health Inc., BIOMERICA INC or Insight Molecular Diagnostics Inc., or pick any stock.

  • TickerNNNN on Nasdaq2
  • IndustryIn Vitro & In Vivo Diagnostic Substances2
  • HeadquartersGrand Cayman, Cayman Islands2
  • Incorporated inCayman Islands4
  • Business addressFriedrich-Ebert-Anlage 49, Frankfurt Am Main, 2M 603084
  • Filer categoryNon-accelerated filer, Emerging growth company4
  • Legal formexempt company2
  • LEI9845006F57813BI984452
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressP. O. Box 31119, KY1-1205 Grand Cayman, Cayman Islands2
  • Registered withGeneral Registry, 3788852

See how the biggest companies compare on our leaderboards

Delaware on March 28, 2023, as a wholly owned subsidiary of LoviWell BVI. LoviWell has no operation as of the date of this annual report.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

87.2%Gross margin3
66.7%Operating margin3
74.1%Net margin3
5.6%Revenue growth, 20253
21.2%Return on equity3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Regions

European Union brought in 60% of the revenue Anbio Biotechnology broke down this way in fiscal 2025.

  1. European Union$5.2M360%down 8% from 2024
  2. Asia Pacific$1.5M318%up 199% from 2024
  3. Other Regions$1.4M316%up 198% from 2024
  4. North America$296.2K33%up 168% from 2024
  5. South America$269.5K33%down 82% from 2024
Regions by year
Regions202320242025
European Union$4.7M$5.6M$5.2M
Asia Pacific$73.4K$509.2K$1.5M
Other Regions$111.0K$472.4K$1.4M
North America$215.4K$110.5K$296.2K
South America$1.7M$1.5M$269.5K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue12¢$1.1M
  • Research and development2¢$201.3K
  • Selling, general and admin17¢$1.6M
  • Profit69¢$6.4M

Out of $8.6M in revenue.3

Financial statements

Revenue63$8.6M in 2025−63% since 2022
0$10.0M$20.0M$30.0M2022: $23.5M$23.5M20222023: $6.7M$6.7M2023−71%2024: $8.2M$8.2M2024+22%2025: $8.6M$8.6M2025+6%
Gross profit63$7.5M in 2025−40% since 2022
0$5.0M$10.0M$15.0M2022: $12.6M$12.6M20222023: $3.4M$3.4M2023−73%2024: $5.9M$5.9M2024+75%2025: $7.5M$7.5M2025+28%
Operating income63$5.8M in 2025−43% since 2022
0$5.0M$10.0M$15.0M2022: $10.2M$10.2M20222023: $2.0M$2.0M2023−81%2024: $2.0M$2.0M2024+2%2025: $5.8M$5.8M2025+189%
Net income63$6.4M in 2025−36% since 2022
0$5.0M$10.0M$15.0M2022: $10.0M$10.0M20222023: $2.3M$2.3M2023−77%2024: $2.4M$2.4M2024+5%2025: $6.4M$6.4M2025+170%
Fiscal year20212022202320242025
Revenue$23.5M6$6.7M3$8.2M3$8.6M3
Cost of revenue$11.0M6$3.4M3$2.3M3$1.1M3
Gross profit$12.6M6$3.4M3$5.9M3$7.5M3
Research and development$200.0K6$134.7K3$454.2K3$201.3K3
Selling, general and admin$2.2M6$1.3M3$3.4M3$1.6M3
Operating expenses$2.4M6$1.4M3$3.9M3$1.8M3
Operating income$10.2M6$2.0M3$2.0M3$5.8M3
Income before tax$10.0M6$2.3M3$2.4M3$6.4M3
Income tax$03$03$03
Net income$10.0M6$2.3M3$2.4M3$6.4M3
Earnings per share$100,112.006$0.103$0.063$0.153
Earnings per share (diluted)$100,112.006$0.103$0.063$0.153
Shares (weighted, basic)100 shares621.4M shares342.3M shares343.7M shares3
Shares (weighted, diluted)21.4M shares342.3M shares343.7M shares3

Compare Anbio Biotechnology with another company

What it owns

What Anbio Biotechnology reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$7.8M3 Dec 31, 2025$11.8M3 Dec 31, 2024−34.0%
Marketable securities, current$4.1M3 Dec 31, 2025$03 Dec 31, 2024

Leadership

Who has led Anbio Biotechnology, and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Suki Song2026–now
  • Chief financial officerSuki Song Apr 8, 2026 to now7
Board members and other officers (4)

Timeline

  1. Jul 27, 2021Founded Anbio Biotechnology is founded2

Filings

43 filings to the SEC since October 2021: 3 annual reports, 7 insider forms, 33 other. The latest 20:

  1. Jul 9, 2026F-3ASR AUTOMATIC SHELF REGISTRATION STATEMENT OF SECURITIES OF WELL-KNOWN SEASONED ISSU EDGAR
  2. Jun 12, 20263 EDGAR
  3. Jun 12, 20263 EDGAR
  4. May 19, 20266-K EDGAR
  5. Apr 27, 20266-K EDGAR
  6. Apr 9, 202620-F/A FORM 20-F/A1 EDGAR
  7. Apr 8, 20263 EDGAR
  8. Apr 8, 20263 EDGAR
  9. Apr 8, 20263 EDGAR
  10. Apr 8, 20263 EDGAR
  11. Apr 8, 20263 EDGAR
  12. Apr 7, 202620-F EDGAR
  13. Feb 17, 20266-K EDGAR
  14. Jan 26, 20266-K EDGAR
  15. Dec 30, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  16. Nov 13, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  17. Apr 28, 202520-F ANNUAL REPORT EDGAR
  18. Feb 21, 20256-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  19. Feb 19, 2025424B4 PROSPECTUS EDGAR
  20. Feb 18, 2025EFFECT EDGAR

The 43 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How Anbio Biotechnology is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAnbio Biotechnology1
  • CIK0001982708
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company5
  • Incorporated inCayman Islands5
  • Fiscal year endsDecember 311
  • Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressFriedrich-Ebert-Anlage 49, Frankfurt Am Main, 2M 603081
  • Phone49160962472811
  • Shares outstanding43,891,200 Common Class A shares; 100,000,000 Common Class B shares as of Dec 31, 20255
  • AuditorGGF CPA LTD, Guangzhou PRC PCAOB ID 2729; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceDec 27, 20231
  • Filings43 in all: 3 (7), 6-K (7), DRS/A (5), DRSLTR (4), UPLOAD (4), F-1/A (3), 20-F (2), CORRESP (2)1
    All 17 form types

    20-F/A (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), EFFECT (1), F-1 (1), F-3ASR (1), FWP (1)

  • Latest filingsAnnual report (20-F) Apr 7, 2026

Securities registered for trading

ClassSymbolExchange
Class A Ordinary Shares, par value $0.0001 per shareNNNNThe Nasdaq Stock Market LLC

From the cover page of the 20-F filed Apr 7, 2026 (Section 12(b) of the Exchange Act).5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11